225Ac and 213Bi is considered as the favorable radionuclide pair for the next generation of Targeted Radionuclide Therapy.
State of the art radionuclides for research on cancer treatments are currently medium range beta emitters such as 177Lu. With the increase of specific activity, for example achieved by the development of n.c.a. 177Lu, therapeutic doses could be delivered not only to the primary tumor, but also to small metastases.
Nevertheless, micrometastases or single cell diseases like leukemia can still not be researched effectively.
For these kinds of cancers, alpha emitting radionuclides such as 213Bi or 225Ac would be the favorable choice. Due to their small penetration range in tissue and their high linear energy transfer (LET) they promise a superior ratio between penetration of cancer cells and protection of healthy tissue.
This product is for laboratory research purposes only